理解终末期肾病发病率与肾脏替代治疗启动的国际差异
在CKDopps队列研究的7381例3至4期慢性肾脏病患者中,3年随访期间1297例进展为终末期肾病、947例启动肾脏替代治疗。调整风险因素后,各国终末期肾病风险与美国相比无显著差异,但肾脏替代治疗启动风险在巴西显著较低、德国显著较高,提示实践差异主要影响替代治疗启动而非疾病进展。
要点
- 调整人口学和eGFR后,巴西、法国、德国终末期肾病风险与美国相比无显著差异。
- 进一步调整合并症、白蛋白尿、收缩压和RAASi处方后,终末期肾病风险比未实质改变。
- 完全调整后,肾脏替代治疗启动风险巴西显著低于美国、德国显著高于美国、法国与美国相似。
核心结论
- 肾脏病患者的CKD进展个体风险因素似乎可解释终末期肾病发病率的大部分国家间差异,但不能解释肾脏替代治疗启动率的差异。
- 这提示肾脏替代治疗启动或可及性相关实践的差异起主要作用,而减缓疾病进展的实践差异作用不突出。
- 使用肾脏替代治疗作为终末期肾病的替代指标可能使CKD进展风险因素关联估计产生偏倚。
研究设计与样本
- CKDopps队列研究,纳入7381例入组时为CKD 3至4期的患者,随访3年。
- 研究比较各国终末期肾病发生率(定义为持续eGFR<15 ml/min per 1.73 m2)和肾脏替代治疗启动率,并逐步调整风险因素、血压控制或RAASi处方实践。
主要发现
- 3年随访期间,1297例进展为终末期肾病,947例启动肾脏替代治疗。
- 与美国相比,人口学和eGFR调整后持续低eGFR的风险比(HR,95%CI)为巴西0.77(95%CI 0.57-1.02)、法国0.90(95%CI 0.75-1.08)、德国1.03(95%CI 0.86-1.03)。
- 进一步调整合并症、白蛋白尿、收缩压和RAASi处方后,上述HR未实质改变。
- 与美国相比,完全调整后肾脏替代治疗启动的HR为巴西0.55(95%CI 0.39-0.79,显著较低)、德国1.36(95%CI 1.09-1.69,显著较高)、法国1.07(95%CI 0.81-1.39,相似)。
临床怎么用
- 原文结论未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Incidence of kidney replacement therapy (KRT) varies widely across countries. Its relations to individual characteristics, nephrology practices for slowing chronic kidney disease (CKD) progression, and KRT access remain unclear. METHODS: We investigated intercountry differences in kidney failure (KF) rate, defined by a sustained estimated glomerular filtration rate (eGFR) <15 ml/min per 1.73 m2, and separately in KRT incidence, before and after adjusting for risk factors and blood pressure (BP) control or renin-angiotensin-aldosterone system inhibitor (RAASi) prescription practices in the CKD Outcomes and Practice Patterns Study (CKDopps) cohort study. RESULTS: Among 7381 patients with CKD stage 3 to 4 at enrollment, 1297 progressed to KF and 947 initiated KRT over a 3-year follow-up period. Compared to the United States, demographic-adjusted and eGFR-adjusted hazard ratios (HRs) (HRs, 95% confidence intervals [CI]) for a sustained low eGFR were 0.77 (95% CI, 0.57-1.02) in Brazil, 0.90 (95% CI, 0.75-1.08) in France, and 1.03 (95% CI, 0.86-1.03) in Germany. Further adjustment for comorbidities, albuminuria, systolic BP, and RAASi prescription did not substantially change these HRs. In contrast, compared with the United States, the fully-adjusted HR for KRT remained significantly lower in Brazil (0.55, 95% CI 0.39-0.79), higher in Germany (95% CI, 1.36, 1.09-1.69), and similar in France (95% CI, 1.07, 0.81-1.39). CONCLUSION: Individual risk factors for CKD progression in nephrology patients appeared to explain most intercountry variations in KF but not KRT incidence. This suggests a prominent role for differences in practices related to KRT initiation or access, but not those for slowing disease progression. This study also shows that using KRT as a KF surrogate may bias estimates of associations with CKD progression risk factors.
引用
- Alencar de Pinho N, Henn L, Raina R, et al. Understanding International Variations in Kidney Failure Incidence and Initiation of Replacement Therapy. Kidney Int Rep. 2022. PMID: 36531894. doi:10.1016/j.ekir.2022.08.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。